Caladrius Biosciences (CLBS) to Release Earnings on Thursday

Caladrius Biosciences (NASDAQ:CLBS) is scheduled to issue its quarterly earnings data after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter.

Caladrius Biosciences (NASDAQ:CLBS) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.05). On average, analysts expect Caladrius Biosciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ:CLBS traded down $0.01 during trading hours on Tuesday, hitting $2.71. The company’s stock had a trading volume of 892 shares, compared to its average volume of 45,768. The stock has a fifty day simple moving average of $2.69. Caladrius Biosciences has a twelve month low of $2.16 and a twelve month high of $6.83.

A number of analysts have recently commented on CLBS shares. Chardan Capital reissued a “buy” rating and set a $6.00 price target on shares of Caladrius Biosciences in a research note on Sunday, May 12th. Zacks Investment Research raised Caladrius Biosciences from a “sell” rating to a “buy” rating and set a $3.25 price target on the stock in a research note on Friday, July 19th. WBB Securities started coverage on Caladrius Biosciences in a research note on Tuesday, May 14th. They set a “speculative buy” rating and a $6.75 price target on the stock. Finally, ValuEngine raised Caladrius Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $8.63.

About Caladrius Biosciences

Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Featured Article: What is a CD ladder?

Earnings History for Caladrius Biosciences (NASDAQ:CLBS)

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.